Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrecipioSTU:TGK 51 EBITDA Margin % is -14.47% as of Mar. 2026. GuruFocus rates STU:TGK with a GF Score™ of 51/100 and a GF Value™ of €2.26. The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Precipio ranks worse than 50.74% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Precipio's EBITDA for the
three
months ended in Mar. 2026 was €-0.84 Mil. Precipio's Revenue for the
three
months ended in Mar. 2026 was €5.81 Mil. Therefore, Precipio's EBITDA margin for the quarter that ended in Mar. 2026 was -14.47%.
Precipio (STU:TGK) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Precipio EBITDA Margin % Related Terms
Precipio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Precipio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:TGK vs QUCY, IDXG, BIOQ: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Precipio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precipio EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Precipio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precipio (STU:TGK) has a EBITDA Margin % of -14.47% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Precipio and its competitors. According to the industry distribution chart, Precipio ranks #103 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 50.7%.
Is Precipio's EBITDA Margin % too high?
Precipio's current EBITDA Margin % is -14.47%. Based on the distribution chart, Precipio ranks #103 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Precipio has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Precipio's EBITDA Margin % compare to QUCY and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Precipio ranks #103 out of 203 companies for EBITDA Margin %. This places Precipio in the lower half of its industry. The industry median EBITDA Margin % is 5.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Precipio and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precipio's current EBITDA Margin % is -14.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precipio stock overvalued right now?
Precipio (STU:TGK) has a current EBITDA Margin % of -14.47%. The stock's GF Value™ is €2.26, compared to a current price of €4.96 — trading 119.5% above its estimated fair value. The current EBITDA Margin % is -14.47%. Precipio's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Precipio (STU:TGK), the current EBITDA Margin % is -14.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precipio (STU:TGK) Overvalued in 2026?
Based on GuruFocus' analysis, Precipio stock appears to be overvalued.
The current stock price of €4.96 is trading 119.5% above its estimated GF Value™ of €2.26.
Key valuation signals for STU:TGK:
EBITDA Margin %: -14.47%
GF Value™: €2.26 vs. price of €4.96 (119.5% above fair value)
No single metric tells the full story. See the STU:TGK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
51GF Score
Get the complete analysis for STU:TGK
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:TGK has been successfully added to your 
